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AbStrAct
The key pathogenic event in prion disease involves misfolding and aggregation of 
the cellular prion protein (PrP). Beyond this fundamental observation, the mechanism 
by which PrP misfolding in neurons leads to injury and death remains enigmatic. Prion 
toxicity may come about by perverting the normal function of PrP. If so, understanding the 
normal function of PrP may help to elucidate the molecular mechansim of prion disease. 
Ablation of the Prnp gene, which encodes PrP, was instrumental for determining that 
the continuous production of PrP is essential for replicating prion infectivity. Since the 
 structure of PrP has not provided any hints to its possible function, and there is no obvious 
 phenotype in PrP KO mice, studies of PrP function have often relied on intuition and 
 serendipity. Here, we enumerate the multitude of phenotypes described in PrP deficient 
mice, many of which manifest themselves only upon physiological challenge. We discuss 
the pleiotropic phenotypes of PrP deficient mice in relation to the possible normal function 
of PrP. The critical question remains open: which of these phenotypes are primary effects 
of PrP deletion and what do they tell us about the function of PrP?
introDuction
The prion protein (PrPC) is a conserved glycoprotein tethered to cell membranes by 
a glycosylphosphatidylinositol (GPI) anchor.1 PrPC denotes “cellular” or “normal” PrP 
to differentiate it from PrPSc for “scrapie” or disease associated isoform of PrPC. PrPC 
is expressed in many tissues, most abundantly in brain, heart, muscle, and also in select 
lymphoid and myeloid cells.2 The role of PrPSc in the pathogenesis of the  transmissible 
spongiform encephalopathies (TSE), the prion diseases, has been intensively studied.1-5 
Conversely, much less attention has been focused on the role of PrPC in normal physiology.6 
Of note, normal function studies of proteins associated with other neurodegenerative 
diseases, such as amyloid precursor protein and the secretases for Alzheimer’s disease,7 
a-synuclein for Parkinson’s disease,8 and huntingtin for Huntington’s disease,9 are helping 
to provide deeper insights into the pathophysiology of these diseases. Analogously, a clearer 
understanding of the function of PrPC in homeostasis may provide valuable insights into 
the molecular pathways of prion pathogenesis. However, the extent of overlap between 
understanding the pathogenic dysfunction of PrPSc in prion diseases and the normal 
 function of PrPC in cell physiology remains to be determined (depicted in Fig. 1).
Many approaches have been utilized to understand the physiological function of PrPC, 
including but not limited to the identification of multiple interaction partners, human 
genetic studies of the Prnp (prion protein gene) locus, ectopic and overexpression of PrPC 
in a variety of cell types and organisms, and finally deletion or ‘knockout’ (KO) studies in 
the mouse,10 cow,11 and even goat,12 providing additional exciting tools for  understanding 
aspects of PrPC physiology that may not be addressable in mice (Fig. 2). The search 
for protein interaction partners of PrPC, by a variety of methods, has led to interesting 
candidates but functional demonstration of the importance of these  interactions is still 
missing.2,13 Furthermore, overexpression and ectopic expression studies of PrPC, or 
expression of mammalian PrPC in lower organisms is yet to reveal an irrefutable  function 
for PrPC. Another approach includes large scale genetic association studies to look for 
PRNP mutations or polymorphisms associated with human genetic disorders. Some 
 interesting genetic associations with Alzheimer’s disease susceptibility have been found but 
lack consensus in the field.14-16 Polymorphisms in PrPC have been associated with rare 
forms of cortical malformation,17 differences in surgical outcome for a form of epilepsy,18 
and even learning and memory.19
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A large pool of PRNP mutations have been identified in humans, 
but all of these are associated with familial prion diseases, or 
appear to represent harmless polymorphisms.20 Perhaps there are 
 heretofore undiscovered humans with small chromosomal deletions 
that  encompass the PRNP locus, or even mutations that render 
humans haploinsufficient or even null for PrP. Such human patients 
may tell us volumes about the function of PrPC and perhaps that it is 
dispensable for normal life as is the case for mice10 and cows.11
Because PrPC is so conserved among mammals, there was great 
expectation that ablation of Prnp in the mouse would reveal a normal 
function for this enigmatic gene.21 Since the PrP KO mice have no 
overt phenotype,10,22 it was clear that PrPC is not essential for the 
survival of the laboratory mouse. However, genetic  compensation 
and developmental plasticity may mask the phenotype of PrPC 
 deficient mice and thus, it may take an appropriate challenge to 
reveal any phenotype. Although the original reports on the Zurich 
and Edinburgh PrP KO mice (two different targeting strategies to 
delete PrP, named after the city where the experiments took place) 
reported “no phenotype”, many subsequent studies have revealed that 
this KO mouse has an abundance of phenotypes, some of which have 
been contested and many of which are subtle (Table 1). This review 
 summarizes the recent research in determining the normal function 
of PrPC by utilizing the PrP KO mouse. Although many claims 
to PrPC  function have been generated from the study of cultured 
cells,3,23 we will mostly confine our discussion to studies utilizing 
mice: the PrP KO, the deletion of the PrPC homolog doppel (Dpl), 
and overexpression transgenics of PrPC and Dpl. Prnp is one of the 
most frequently knocked out mammalian genes, and a plethora of 
PrP-deficient mice have been generated with a wealth of strategies. 
Detailed reviews of the construction of the various available PrP 
KO mice exists.24,25 The neurodegeneration caused by the ectopic 
expression of Dpl in the Nagasaki and Rcm PrP KO (generated with 
a different gene targeting strategy than the Zurich and Edinburgh PrP 
KOs) has been reviewed in detail,24,25 and will be discussed only in 
so far as PrPC and Dpl function(s) are concerned.
the cAveAtS of A PhenotyPe
Given the abundance of phenotypes attributed to the deletion 
of PrP, we will first discuss several technical concerns relating to 
KO studies and potential caveats of phenotypes in PrP KO mice. 
The advent of “gene-targeting”, or the specific deletion/replacement 
of chromosomal segments, in mice has revolutionized functional 
studies of mammalian genes in vivo. However, technical aspects of 
generating gene-targeted mice from embryonic stem cells can create 
a potential caveat to interpreting phenotypic data. This caveat arises 
because often the resultant mice utilized for functional studies are 
maintained on “mixed” genetic backgrounds, a random mixture of 
alleles from embryonic stem cells (often a 129 sub-strain) and the 
parental line (C57Bl/6, Balb/c, or others). Three concerns arise when 
working on mice of a mixed genetic background, which encom-
pass most studies of PrP KO mice: 1) increases in the phenotypic 
variability and thus a higher chance of spurious results 2) the hetero-
zygosity at many loci increases the noise of most measurements, 
potentially obscuring subtle phenotypes, and 3) the possibility that 
alleles linked to the deleted gene (which is continually selected for by 
 investigators during breeding) are actually responsible for the pheno-
type in  question.26 Another point to consider is that depending on 
how the investigator maintains the KO line (either by inbreeding 
separate populations of PrP-/- and PrP+/+, or by intercrossing 
PrP+/- mice) we also have to contend with genetic drift, that is the 
tendency for certain alleles to become “fixed” (100% frequency) in 
populations simply by chance.
The availability of the fully-sequenced mouse genome, in concert 
with physical maps of polymorphic short-tandem repeats, would 
allow for eliminating the confounding genetic factors  enumerated 
above. For example, the “speed congenic” technologies which 
are being offered commercially—but can be enacted in-house by 
Figure 1. The overlap between the normal function of PrPC and the 
 pathogenic dysfunction of PrPSc in disease depicted as a Venn diagram. The 
extent of overlap between the normal function of PrPC and its role in prion 
disease is open to speculation, the circles could have a much greater or 
perhaps even less overlap.
Figure 2. Different approaches to study PrPC’s normal function. There are 
many ways to approach the study of the normal function of PrPC, none of 
which have conclusively demonstrated PrPC’s function. Interacting partners of 
PrPC have yielded many interesting candidates, human genetic studies have 
found associations of PrPC with diseases beyond prion disease and even to 
learning and memory, over‑ and ectopic‑expression studies constitute another 
approach to determine the function of PrPC, and finally, the focus of this 
review, the PrP KO has given some clues to the function of PrPC.
www.landesbioscience.com Prion 85
Prion Protein Knockout Mouse Phenotypes
real-time PCR and sequencing—enable selective breeding of mice 
that are genetically homogeneous at any given chromosomal region. 
However, almost none of the phenotypes described in the following 
pages have been ascertained using such genetic controls—and this 
represents a major caveat in the interpretation of phenotypic data. Of 
the various PrP KOs that have been generated,25 only the Edinburgh 
KO has been maintained on a pure 129/Ola background22 and this 
strain background is notoriously difficult to work with because of 
poor breeding and several other abnormalities.26 Backcrossing PrP 
KOs onto a pure genetic background helps to eliminate this concern. 
However, despite intensive backcrossing, regions on the  chromosome 
adjacent to the Prnp locus are carried along through all the 
 generations of backcrossing, such that even after 12  generations of 
backcross the KO allele would be flanked by about 1% of the ES cell 
genome.26 As a consequence, it is difficult to conclude with certainty 
that a phenotype is due to the genetic background of the mouse or 
the deleted gene in question. Another point worth considering is that 
on pure backgrounds it is possible to obtain a phenotype that is a 
combination of the deletion in question (i.e., PrP KO) and a specific 
allele(s) of the background (i.e., a C57Bl/6 allele of a gene). Such a 
KO and strain background synergistic phenotype would be difficult 
to replicate unless other investigators are using the same mice.
Rescue experiments, whereby a transgene is reintroduced into 
the KO to rescue a phenotype, are time-consuming and are not 
“fool-proof”, but represent one approach toward eliminating an 
effect of a linked allele or a chance observation in a mixed genetic 
background. On the other hand, such reliance on rescue experiments 
led to the erroneous assignment of pathological phenotypes to the 
deficiency of PrP (in Nagasaki PrP KOs),27 whereas the phenotype 
was in reality brought about by the overexpression of Dpl in a PrP 
KO background.25
A separate concern from genetic background arises from  intensive 
and multi-faceted hunting for phenotypes. Since all biological 
measurements, but particularly those made on animals, are associated 
with intrinsic variability, we expect to find some spurious phenotypes 
just by chance. For example, if the null hypothesis is that PrP KOs are 
not different from wild-type with a conventional threshold of signifi-
cance of p < 0.05, we expect that if 100 labs study the PrP KO that as 
many as five may find spurious phenotypes. This is an example of the 
“multiple hypothesis testing problem” and is an inescapable reality of 
biological research. Independent confirmation of findings in more 
than one type of the PrP KO mouse, for example the Edinburgh or 
Zurich PrP KOs, or by more than one laboratory will be important 
for building confidence in PrP KO phenotypes.
the cLeAreSt of PrP PhenotyPeS: PrP KnocKout mice  
Are reSiStAnt to Prion infection AnD cAnnot rePLicAte 
PrionS
To date, the clearest phenotype of the PrP KO is resistance to 
infection with prions.28,29 This experiment—originally designed 
to disprove the prion hypothesis21—solidified its central tenet: 
the requirement of a host protein for prion replication. Further 
variations of this experiment have taught us that PrPC expression 
is required for prion-induced toxicity.30 Neurografting brain tissue 
from wild-type mice into PrP KO brains revealed that Prnp+/+ tissue 
grafts  replicated prions with accompanying damage to neurons 
while nearby PrP-deficient tissue was unharmed.31 Thus, PrPC on 
neuronal cells is required for prion propagation associated toxicity. 
This evidence supports our conjecture that deciphering the normal 
function or signaling pathway through which PrPC operates will help 
illuminate the devastating sequence of events in prion disease.
The PrP KO mouse enabled another important series of studies 
that defined some of the sequence elements required for PrPSc to 
retain infectivity by expressing truncated PrP transgenes on the KO 
background and infecting these mice with prions. This approach 
revealed that the octapeptide repeats (Fig. 3) were not necessary for 
prion replication or toxicity, but indicated that they may be required 
for the rampant spongiosis and production of high titers of prion 
infectivity normally associated with prion diseases.32,33
PrP in SLeeP reguLAtion
Sleep disturbances and altered circadian rhythms were the first 
documented phenotypes in PrP KOs,34 other than the resistance 
to prion infection which is technically a lack of a phenotype.28 
PrPC might be involved in regulating sleep, as certain mutations in 
PRNP cause a prion disease known as fatal familial insomnia.35 This 
disease eventually results in broadly disseminated neurodegeneration 
but one key symptom is a nearly complete inability to sleep. Sleep 
deficits are also a documented feature in human Creutzfeldt-Jakob 
disease of sporadic origin.36 Tobler and colleagues found that during 
a normal light/dark cycle PrP KOs had similar patterns of running 
wheel activity as controls. However, in constant darkness, wild-type 
mice display a shorter circadian period (as is customary for wild-type 
mice without circadian cues) whereas PrP KOs remarkably  maintain 
a normal period as if still “entrained” by light.34 This finding was 
shown in both the Edinburgh and Zurich PrP KOs. Further studies by 
Tobler and colleagues revealed that PrP KOs have more fragmented 
sleep episodes than do controls, leading the authors to conclude 
that PrPC plays a role in promoting sleep continuity.37 The fact 
that PrPC alters sleep and that PrPSc production also leads to sleep 
 abnormalities supports our hypothesis that understanding PrPC 
 function will help to understand prion disease. But in nearly a decade 
since this  phenotype was documented there is still no clarity as to 
how PrPC regulates sleep at a molecular level.
A roLe for PrP in oxiDAtive StreSS:  
coPPer binDing, SoD‑Activity AnD mitochonDriA
A considerable amount of work has focused on the copper (Cu) 
binding and potential anti-oxidant function of PrPC. The genesis 
of this work is the observation that recombinant PrPC binds to Cu 
and that copper levels were diminished in brains of PrP KOs.38 The 
ability of PrPC to bind Cu has been well supported but  alteration in 
Cu content in PrP KO brains is controversial.39 A study by Wong 
et al. suggests that PrPC is involved in defense against  oxidative 
damage.40 They observed higher levels of oxidized proteins and 
lipids in the brains of Edinburgh PrP KOs.40 A similar situation was 
observed in Zurich PrP KOs by Klamt and colleagues, who further 
found that superoxide dismutase (SOD) activity was significantly 
decreased in the brain and muscle of PrP KOs.41 On the other hand, 
Waggoner et al. could not detect differences in enzymatic activity 
of Cu-Zn  superoxide dismutase.39 This may be due to differences 
in  experimental conditions.42 However, mouse genetic experiments 
argue against a SOD-like activity for PrPC in vivo.43 We reasoned 
Prion Protein Knockout Mouse Phenotypes
86 Prion 2007; Vol. 1 Issue 2
that if PrPC has a SOD activity, then deficiency in both PrPC and 
SOD1 will result in diminished SOD activity compared to deficiency 
in SOD1 only, and conversely PrPC overexpression in a SOD1 KO 
or WT background will result in increased SOD activity. However, 
these genetically defined crosses did not reveal any  alterations in 
SOD activity with respect to PrPC deletion.43
One intriguing phenotype at the cellular level is the  reduction 
in number of mitochondria per cell in the CA1 region of the 
h ippocampus and in the myocardium of Edinburgh PrP KOs.44 The 
mice used in this study were inbred 129/Ola strain, which reduces 
the likelihood of genetic background artifacts but could also result in 
strain specific effect of a gene deletion (discussed above). This study 
was stimulated by the identification of differentially expressed genes 
in the PrP KO, revealing only three genes that were differentially 
expressed-all of which were involved in mitochondrial  biogenesis 
and physiology.44 Also, mitochondria having  morphological 
 abnormalities were more abundant in the PrP KO (Edinburgh).44 It is 
 noteworthy that we identified swollen mitochondria in a  transgenic 
model of prion disease, where PrP is mislocalized to the cytosol, 
another possible connection between PrPC in normal physiology 
and disease.45 Lobao-Soares and colleagues sought to extend the 
 observation of abnormal mitochondria in PrP KOs to a functional 
level by measuring mitochondrial respiration in several regions of PrP 
KO brains, but found similar levels between PrP KOs and controls 
in all regions examined.46 However, it should be noted that isolated 
mitochondria were utilized in this study and it is possible that small 
numbers of abnormal mitochondria may not be detected by their 
assays. Further studies will be required to clarify the role of PrPC—if 
any—in oxidative stress and mitochondrial physiology.
the roLe of PrP in the immune SyStem, PhAgocytoSiS 
AnD AS A microbiAL recePtor
Recent reports have suggested a role for PrPC in cellular 
 internalization pathways, perhaps a function that has been  co-opted 
by microbes. Work from Rafael Linden and colleagues add to the 
growing list of phenotypes for the PrP KO. Prnp null macrophages 
displayed increased rates of phagocytosis in vitro and in vivo, leading 
to the conclusion that under physiological conditions PrPC  negatively 
regulates  phagocytosis.47 This is extremely surprising since the expres-
sion levels of PrPC in macrophages are  typically below the limits of 
 detection (Christina Sigurdson and A. Aguzzi, unpublished data). 
Studies of  microbial pathogenesis in PrP KOs may be connected 
with a role for PrPC in phagocytosis or  cytokine  production. Watarai 
and colleagues have discovered that the PrP KO is more resistant 
to  infection with the bacterial pathogen Brucella abortus.48,49 
Localization and biochemical experiments pinpointed bacterial heat 
shock protein 60 as an interaction partner with PrPC on the cell 
surface.48 It would be interesting to examine the  consequences of 
PrPC overexpression and B. abortus infection. These results were not 
confirmed in a different laboratory in studies using B. suis.50
Virologists have made use of the PrP KO as well, revealing yet 
another phenotype likely relating to cellular internalization  pathways. 
In this study, Thackray and Bujdoso demonstrate that PrP KOs are 
refractory to infection with a neurotropic herpes simplex virus whereas 
PrP overexpression transgenics (Tga20) were highly  susceptible to 
infection.51 Studies of viral titers and maturation markers suggest that 
viral replication is retarded in PrP KOs in favor of establishing latency. 
Intriguingly, the viral infection induced neuronal cell death much 
more dramatically in PrP overexpression transgenics, connecting PrPC 
to cell survival pathways (discussed below). Several of these findings 
were confirmed in a follow-up study by the same group.52
Recent work suggests that PrPC may play a role in the 
 immunological synapse. Ballerini et al., demonstrated that PrPC is 
important in an interaction between T cells and dendritic cell.53 PrPC 
was dispensable on T cells for this interaction but PrPC on dendritic 
cells was important in stimulating T cells in vitro and in vivo assay.53 
Another study reports that aβ T cells are greatly diminished in tga20 
PrP overexpression transgenic mice, and these mice also display an 
atrophy of the thymus.54 However, this  phenotype may represent 
an insertional mutagenesis artifact since tga19 transgenic mice 
derived from the same construct do not show these anomalies (AA, 
unpublished data). One study has attempted to link copper uptake 
and interleukin expression in T cells, finding a slight delay in inter-
leukin-2 expression in PrP KO T cells.55 To summarize, PrPC may 
be important for host-pathogen interactions, immune synapses and 
T cell homeostasis, but further studies will be needed to decipher the 
role of PrPC in the immune system.
neuronAL excitAbiLity
The high level of PrPC expression in neuronal cells led to an 
interest in detecting electrophysiological defects in the PrP KO. This 
topic is no less controversial than any other we have discussed in 
this review, but the weight of the evidence clearly lies on the side of 
altered neuronal excitability in PrP KO neurons. Electrophysiological 
studies of PrP KOs were first under-taken by John Collinge and 
John Jefferys, who found that CA1 neurons in Zurich PrP KOs had 
faster after-hyperpolarization currents and were impaired in long 
term potentiation (LTP).56 Jean Manson and colleagues had similar 
findings in purebred Edinburgh PrP KOs.57 In addition it was shown 
that both wild-type and a familial mutant human PrPC were capable 
of rescuing this electrophysiological phenotype when expressed as 
transgenes in the PrP KO background.58,59 Soon after these  findings 
were reported opposing reports surfaced. Herms et al. examined 
synaptic transmission in Purkinje cells of Zurich PrP KOs but did 
not detect any differences from controls.60 Another group found no 
differences between Zurich PrP KOs and controls in the CA1 region 
of the hippocampus.61 Over the ensuing years there have been several 
other attempts to clarify the electrophysiological  phenotype (or 
lack thereof ) in PrP KOs.62-64 However, only one thing is clear—
 detection of the electrophysiological phenotype depends on which 
line of mice is being used, who is investigating, and the age of the 
PrP KOs being used.65 It is worth noting that authors on two of the 
papers reporting “no phenotype”60,61 have reversed their  position in 
later studies.66,67 Finally, the post natal neuronal-specific KO of PrPC 
showed a  reduction of after-hyperpolarization potentials in neurons 
in CA1,68 an identical phenotype to what had been  originally 
reported by Collinge and colleagues.56
The neuronal excitability phenotypes may relate to one of the 
strongest phenotypes of PrP KOs, which presents under the challenge 
of seizure inducing drugs. Zurich PrP KOs are much more  susceptible 
to repeated doses of pentylene tetrazol and kainic acid, both of 
which induce seizures.69 Approximately 50% of PrP KOs died 
from a single administration of kainic acid while 100% of control 
animals survived.69 This result has been confirmed independently 
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by Rangel, et al., who also note increased neuronal cell death in PrP 
KOs injected with kainic acid.70 The increased seizure sensitivity may 
be due to higher levels of ectonucleotidase activity which destroys 
adenosine, an endogenous anticonvulsant agent, in PrP KOs.71,72 
Finally, it is also worth noting that a defect in neuronal architecture 
of the  hippocampus in Zurich PrP deficient mice has been reported 
and may be relevant to several of the findings discussed above.73 
Timm stained sections of the hippocampus from PrP KO had more 
sprouting of axons than did controls in the granule cell layer of the 
dentate gyrus and the infrapyramidal region of CA3 region.73 This 
is said to resemble the mossy fiber collateral and terminal sprouting 
seen in certain human epilepsies.
behAviorAL PhenotyPeS: iS PrP invoLveD  
in LeArning AnD memory?
If they bear any relevance to real life, the electrophysiological 
defects described above for the PrPC null neurons might manifest 
in the behavior of the PrP KO mouse. The abundant expression 
of PrPC in regions important in learning and memory, such as 
the  hippocampus, has lead to a series of behavioral studies aimed 
at detecting abnormalities in PrP KOs. Initial studies by Charles 
Weissmann, Hans Peter Lipp, and colleagues did not detect any 
phenotype of Zurich PrP KOs in a long-term study using maze 
tests.10,74 Further, a study by Roesler et al. failed to detect any 
abnormalities in anxiety nor inhibitory avoidance learning in PrP 
KOs.75 Cognitive defects have been detected in PrP KOs by Criado 
and colleagues who found that spatial learning was defective in PrP 
KOs.62 This phenotype was PrP-dependent as it was rescued by 
crossing PrP KO mice with a transgene driving expression of hamster 
PrPC under a neuron-specific promoter.62 Another study describes 
PrP KOs as having normal short- and long-term memory at three 
months of age but impairments by 9 months of age.76 Aged PrP KOs 
also showed less exploratory activity in an open field.76 A follow-up 
study suggested that the interaction of PrPC and laminin may be key 
to memory consolidation in rats,77although there is no clarity about 
which molecular events might be triggered by the binding of PrPC 
to laminin. Finally, a study in humans suggests that the M129V 
 polymorphism in PrPC, which influences susceptibility to prion 
infection in humans-may be involved in learning and memory.19
In an attempt to reveal a behavioral phenotype, investigators 
have challenged PrP KOs in various ways during phenotypic testing. 
Coitinho et al. dosed PrP KO mice with various psychotropic 
drugs and interestingly, PrP KOs show a decreased response to the 
psychotropic drug MK-801, which normally causes increased motor 
activity.78 Amphetamine and caffeine induced hyper-locomotion 
to an equal extent in PrP KOs and controls.78 Nico et al. subjected 
Zurich PrP KOs to acute stress by foot shock or swimming trial and 
found that PrP KOs showed less anxiety than controls after these 
treatments.79 In non-stress conditions, PrP KOs appeared identical 
to controls.79 Another study notes a very subtle increase in locomotor 
activity in PrP KOs in an open field test.75 This increased locomotor 
activity has not been observed using extensively backcrossed C57Bl/6 
PrP KOs (both Edinburgh and Zurich) in the home cage using high 
Figure 3. A model for the effects of PrPC deletion and deletion mutants of PrPC. (A) Schematic diagram of wild‑type PrPC and deletion mutants. SP, signal 
 peptide; octapeptide repeats are indicated in blue; CC, charge cluster; HC, hydrophobic core; H1, H2, H3 Helix 1,2 and 3, respectively; GFP, GPI‑anchor 
addition sequence (B). PrP (black) consists of a globular C‑terminal domain (hexagon) and a N‑terminal flexible tail (arch) encompassing the octapeptide 
repeats (ORs) (circle). The model rests on the following assumptions: (1) PrP activates a hitherto unidentified receptor (PrPR) which transmits myelin  maintenance 
signals (flashes); (2) in the absence of PrP, PrPR exerts some residual activity, either constitutively or by recruiting a surrogate ligand; (3) the activity of PrP and 
its mutants requires homo‑ or heterodimerization, and induces dimerization of PrPR; and (4) PrP dimers containing PrPDCD or PrPDCD trap PrPR in an inactive 
dominant‑negative state. Finally, (5) the OR region stabilizes the interaction between PrP and PrPR, but does not contribute directly to signaling.
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resolution techniques recently used to study prion disease in detail,80 
however, our testing conditions are not equivalent to an open field 
test (ADS and SL, unpublished results).
DiverSe neuroProtective ProPertieS of PrP
Many studies have claimed that protection against neuronal 
damage is one of PrPC’s raison d’être. Neuroprotection (defined 
generically as protecting neurons from dysfunction or death) 
may represent one of the best-supported functions of PrPC. This 
 protection applies to both physiological challenges and to a  peculiar 
yet fascinating paradigm whereby the closest homolog of PrPC, 
Dpl, when ectopically expressed in the brain causes loss of Purkinje 
neurons in the cerebellum but only in a PrP KO background.27
We will begin our discussion of PrP’s protective properties with 
one of the most agreed upon observations-PrP KOs are much more 
susceptible to ischemic damage. McLennan and colleagues were the 
first to document that PrP KOs are more susceptible to stroke.81 They 
were led to the PrP KO through studying a dramatic upregulation 
of PrP expression at sites of stroke in human brains.81 Subsequent 
studies have replicated and extended these results in acute82 and 
long term models of ischemia83 and even in transgenic rats.84 
Interestingly, transgenic overexpression of PrP in the mouse does not 
protect above wild-type PrP levels85 while in the rat increasing PrP 
levels did confer protection. Weise and colleagues note that PrP KOs 
have lower levels of phosphorylated-Akt both in basal  conditions 
and during ischemic injury, pointing towards a general role of PrP 
in activation of cell survival pathways.83 Other researchers have 
noted significant increases in the phosphorylation of ERK-1 and -2, 
STAT-1, and JNK-1 in ischemic PrP KO brains.85 Recently, Gains 
and colleagues have extended PrP’s neuroprotective spectrum. They 
dosed neonatal PrP KOs and controls with a high dose of ethanol, 
a paradigm for inducing Bax mediated apoptosis, and noted a 
dramatic increase in cell death in brains of PrP KOs.86 Another brief 
report documents an enhanced brain injury in PrP KOs after head 
trauma,87 however, it is likely that these mice overexpress Dpl and 
therefore display a confounding effect. To test PrP’s neuroprotective 
function in another setting, we crossed PrP KOs to several transgenic 
models of neurodegenerative disease—Huntington’s, Parkinson’s and 
Alzheimer’s disease. Much to our surprise, the phenotypes of these 
diseases were largely unaltered by PrP deletion (ADS, Z. Zhou, 
W. Jackson, M. Moskowitz, S. Lindquist, unpublished). Thus, the 
wide-ranging neuroprotective functions of PrP have  limitations 
and these observations of protection in unique models need to be 
 understood in mechanistic detail.
The second well-studied paradigm in which PrP exerts a  protective 
function deals with the neurotoxicity induced by its nearest homolog. 
The exciting and circuitous discovery of Dpl began with conflicting 
reports on the phenotype of the PrP KO, with two groups reporting 
no phenotype10,22 and one group reporting a late onset ataxia 
and Purkinje cell loss in Nagasaki PrP KO mice.27,88 Later it was 
determined by several groups that a previously undescribed tightly 
linked homolog of PrPC (called “doppel” for “Downstream of the 
Prnp locus”) was upregulated by the deletion strategy used in the 
Nagasaki PrP KO line. The Nagasaki deletion strategy fused PrP’s 
promoter to Dpl, driving expression of Dpl in the brain, where it 
is not normally expressed.89,90 Subsequent experiments determined 
that the toxicity induced by ectopic Dpl expression in the PrP KO is 
abrogated by  reintroduction of a single copy of PrPC.91,92 However, 
both Weissmann and Katamine have shown that PrPC cannot 
suppress higher amounts of transgene driven Dpl expression,93,94 
suggesting that Dpl and PrPC are competitive antagonists and 
can be  stoichiometrically titrated against each other. Interestingly, 
PrPC devoid of the octapeptide repeats (amino acids 23–88) is 
incapable of rescuing Dpl toxicity, suggesting an important role for 
the N-proximal region of PrPC in its neuroprotective functions.95 
However, a trafficking defect in this deletion mutant of PrP was 
not ruled out, so PrP may not be reaching the cell surface in these 
transgenic mice.
A similar phenomenon is observed when an artificial deletion 
mutant of PrPC, missing amino acids 32-134 and termed “DF”, 
is expressed as a transgene in the PrP KO. This trangenic mouse 
develops a dramatic loss of granular neurons in the cerebellum, 
referred to as “Shmerling syndrome” (Fig. 3a).96 The deletions of 
amino acids 32-121 or 32-134, but not shorter deletions of the 
N-terminus, caused this phenotype. The “DF” truncated PrPC 
targeted specifically to Purkinje cells causes these cells to die in a PrP 
KO background showing that this is a cell-autonomous phenomenon 
akin to Dpl toxicity.97 It has also become clear that truncated PrPC 
and Dpl are toxic to myelinated cells in a PrP KO background.98 The 
white matter pathology was detected in the cerebellum, brainstem, 
and spinal cord in “DF” mice and extended more broadly in Dpl 
overexpression where it was also found in the forebrain, pyramidal 
projections, and the corpus callosum.98 Further deletion mapping 
of PrPC has narrowed the critical region to forty amino acids in 
the middle of PrP, 94-134. When PrP lacking these amino acids is 
expressed in PrP KOs it results in a severe motor phenotype brought 
about by extensive central and peripheral myelin degeneration 
(Fig. 3A).99 PrPC lacking the octapeptide repeats was able to rescue 
this deletion mutant induced phenotype unlike the case of Dpl 
toxicity discussed above.
Most interestingly, careful histopathological analysis clearly 
 identified a myelin degeneration phenotype in PrP KO mice.91,99 
Since this phenotype is seen both in Zurich I and in Nagasaki 
mice, it cannot result from spurious overexpression of Dpl and may 
indeed represent a consequence of PrP deficiency. The similarity 
of this phenotype to Shmerling’s syndrome is striking—although 
Shmerling’s syndrome is much more severe and is visible in much 
younger mice. This finding suggests that myelin maintenance may 
represent an important physiological function of PrPC, and that the 
defects seen in Shmerling’s disease may represent an exaggerated form 
of a PrPC deficiency syndrome.
In the studies discussed above, all toxic mutants displayed 
 disruption of the charge cluster (CC, residues 95–110) and a part 
of the hydrophobic core (HC, residues 111–121) of PrP (Fig. 3). 
Toxicity was ameliorated by co-expressing PrP variants with intact 
CC and HC, even if these variants lacked the octarepeat region. We 
therefore posit that PrP exerts its neuroprotective activity by  signalling 
through the central domain to an unknown receptor  (tentatively 
termed PrPR). In all paradigms investigated, the  phenotype was 
determined by the stoichiometry of mutant to full-length PrP, 
suggesting that PrP, any of the various PrP mutants, and PrPR 
form  hetero-oligomeric complexes (Fig. 3B). The mild  pathological 
 phenotype of PrP KO mice suggests that myelin integrity is supported 
by residual PrPR activity, whereas disruption of the central domain 
(CD) domain sequesters PrPR in a dominant-negative state. Complex 
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stability could be  influenced by domains distinct from those involved 
in executing signal transduction: the context-dependent toxicity 
of PrP missing part of the hydrophobic core (PrPDpHC) implicates 
the octapeptide repreat as one such domain.99 Although deletion 
of 40 amino acids produced a powerfully toxic molecule, ablation 
of eight amino acids within this domain (PrPDpHC) was innocuous 
to both wild-type and PrP KO mice. Crossing  experiments show 
that PrPDpHC is not functionally equivalent to PrP. The toxicity 
of PrPDF was diminished, yet that of PrPDCD was augmented by 
 coexpression of PrPDpHC. In the frame of the signaling model, 
the deletion in PrPDpHC may affect the  interaction between PrP 
and PrPR. Verification of the model presented above requires the 
physical  identification of PrPR. Towards that goal, it will be crucial 
to  identify the cellular  constituents, which may not necessarily all 
consist of protein, binding differentially to PrPC.
A roLe for PrP in Stem/Progenitor ceLL bioLogy
Recently, it was demonstrated that PrPC is expressed on the 
surface of hematopoietic stem cells.100 Zhang and colleagues then 
challenged PrP KO bone marrow with serial transplantations into 
lethally  irradiated recipient mice. After several  transplantations, the 
 repopulating potential of PrP KO bone marrow was exhausted whereas 
control bone marrow was still competent to  repopulate lethally 
 irradiated recipient mice, demonstrating that PrP KO  hematopoietic 
stem cells were deficient in “self-renewal”.100 Reintroduction of PrP 
into PrP null bone marrow cells rescued this defect in self-renewal, 
arguing against an artifact of genetic background. The molecular 
pathway by which PrP promotes the self-renewal of hematopoietic 
stem cells remains unclear but is consistent with many of the suggested 
 protective functions of PrPC. The studies of PrPC in hematopoietic 
Table 1 Proposed functions for PrP from analysis of PrP knockout mice
Phenotype in PrP Ko reference confirmed? opposing?
 circadian/Sleep regulation
Abnormal circadian rhythm 34
Interrupted sleep patterns 37 
 oxidative stress: copper binding,  
 SoD‑activity and mitochondria   
Decreased copper content in brain 38  39
Decreased SOD activity; increased oxidative damage 40, 42 41 39, 43, 46
Reduction/abnormal mitochondria 44  46
 immune system, phagocytosis  
 and as a microbial receptor
Increased phagocytosis 47  
Resistance to infection with B. abortus 48  50
Resistance to infection with HSV‑1 51 52 
Immune synapse, T cell response 53
Interleukin expression 55  
 neuronal excitability
Impaired long term potentiation 56 62, 59, 67, 64, 66,  60, 61, 63, 65 
  57, 58 
Increased susceptibility to seizures 69 70
Mossy fiber disorganization in hippocampus 73
 behavioral phenotypes
Cognitive defects/memory impairment 76, 62  10
Increased locomotor / exploratory activity 75 76
Increased hyperlocomotion induced by MK‑801 78
Decreased anxiety 79
 neuroprotection
Susceptible to Dpl toxicity 27 89–92
Susceptible to “DF” PrP induced toxicity 96 97, 98
Enhanced susceptibility to ischemia 81 82,83,85
Enhanced susceptibility to ethanol induced apoptosis 86
Enhanced susceptibility to traumatic brain injury 87
 Stem/precursor cells
Impaired self‑renewal of hematopoietic stem cells 100
Decreased proliferation of neural precursors 102
 miscellaneous
Abnormality in dentin in teeth 109
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stem cells prompted an examination of PrPC was expression/function 
in neural stem/precursor cells in the adult brain. Adult neurogenesis 
is normally neuroanatomically restricted to the dentate gyrus of the 
hippocampus and the subventricular zone.101 We pulse labeled BrdU 
into PrP KO and overexpression transgenics and noted that in the 
dentate gyrus PrP KOs had a lower level of proliferating cells whereas 
in the PrPC overexpression  transgenic cell proliferation was enhanced 
in the subventricular zone.102 Culturing of neural  progenitor cells 
from embryonic PrP KOs and  overexpression  transgenics revealed 
that PrPC may promote the exit from a precursor state and  maturation 
into a neuronal lineage.102 The signaling pathway through which 
PrPC presumably operates in this process is still undetermined. 
Collectively, these results demonstrate that careful scrutiny reveals a 
subtle function for PrPC in stem and precursor cell biology and it will 
be interesting to examine whether PrPC functions in other adult stem 
cell populations that can be more readily isolated. In concert with the 
possible protection against seizure, ischemia, pathogen infection, and 
evolutionary conservation of PrPC, these results add to the evidence 
for its relevance to mammalian physiology.
future ProSPectS for Determining PrP function  
from in vivo StuDieS: beyonD the Prion Protein 
KnocKout mouSe
Several investigators have expressed PrPC in yeast in order to 
better understand the disease-associated properties of this protein.103 
Furthermore PrPC has been expressed in yeast (which do not express 
a PrP homolog) to investigate normal function, but perhaps this is 
aiming too “low” in terms of model organisms as initial studies have 
not revealed any role for PrPC in copper transport, a well  characterized 
process in yeast.104 Interestingly PrPC expression rescues Bax induced 
cell death in yeast;105 however the significance and relevance of 
this paradigm is unclear even in mammalian cells.106 Given the 
remarkable conservation of PrP structure among vertebrates,107,108 
the use of non-mammalian models could open up new avenues for 
prion research. For instance, the first dramatic phenotypes of PrP 
loss- and gain-of-function have been produced in zebrafish (Edward 
Málaga-Trillo, Gonzalo Solis, Yvonne Schrock, Lydia Luncz, Venus 
Thomanetz, and Claudia Stuermer, personal communication). 
Notably, early knockdown of PrP in fish embryos is lethal but can be 
partially rescued by expression of mouse PrP, ruling out potential off 
target effects of the knockdown construct. Analysis of the molecular 
pathways involved in fish PrP function should guide future studies 
in the mammalian system. Studies in the rat offer the advantage 
of larger brains that make surgical and other interventions more 
feasible.77 However, it is unlikely that deletion of PrPC will be much 
more informative in the rat than it has been for the mouse. Very 
recently it has become possible to study PrPC function in  ruminants 
lacking PrPC which appear normal up to 20 months of age.11 Also, 
hemizygous PrPC deletion goats now exist and homozygous null 
animals should be forthcoming.12 Perhaps the longer lifespans of 
the cow and goat will reveal age dependent  phenotypes associated 
with PrPC deletion. Likewise it may be worthwhile to delete Prnp in 
a non-human primate, where much more detailed cognitive testing 
could be conducted. That being said, it remains possible that the PrP 
KO mouse holds the key to understanding PrPC function, perhaps 
even through the study of unexpected phenotypes, such as the 
recently reported tooth abnormality in PrP KOs.109
Looking to PrPC’s closest homologue in the mouse, Dpl, may be 
fruitful for determining the function of PrPC. Interestingly, the Dpl 
KO results in male sterility,110,111 a phenotype that can be rescued 
by testis specific expression of a PrP with an N-terminal deletion 
in the testes suggesting a functional equivalence of Dpl and the C 
terminus of PrP (A. Aguzzi, unpublished results). Deletion of both 
PrPC and Dpl (dKO) had no discernable phenotypes aside from the 
male infertility present in Dpl KOs.112,113 Deciphering the pathway 
through which Dpl affects male fertility could inform future studies 
of PrPC  function. A more distant cousin of PrP, called “Shadoo”114 
may also hold promise for revealing PrPC’s function.
Will the transgenic mice expressing PrPC without a GPI anchor 
(GPI-) prove useful for elucidating the normal or the disease function 
of PrP? These mice are very intriguing because replication of prion 
infectivity is more or less unaffected whereas toxicity is significantly 
suppressed in the PrP KO background.115,116 It may be that the 
hypothesized signal transduction properties of PrPC are defective 
without a GPI anchor attachment, leaving the GPI—mice fully 
competent for PrPC’s only ironclad function—prion replication. This 
mouse provides an excellent tool in distinguishing PrPSc replication 
from toxicity.
There are many unresolved questions with respect to PrPC 
 function: What is the connection between PrP function and 
 pathogenesis? What is the functional relevance of differential 
 expression of PrPC in subpopulations of neurons in the brain? How 
do we assign the many described phenotypes in PrP KOs to discrete 
molecular pathways? Perhaps physiological stress will only bring out 
the effects of non-relevant linked genes, leading down a garden path 
of genetic artifacts? Is the conformational diversity attained by PrPSc 
reflecting a possible conformational diversity of PrPC as recently 
speculated by Stanley Prusiner?117 It is fascinating to speculate that 
this labile structure of PrPC may encipher its function. Hopefully one 
day the question of PrPC function will be settled, but for now there 
remains plenty of work to do!
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